Decreased 5-hydroxymethylcytosine levels are associated with TET2 mutation and unfavorable overall survival in myelodysplastic syndromes

Leukemia and Lymphoma

Volumn 54, Issue 11, 2013, Pages 2466-2473

  Liu, Xiaoliu ^a   Zhang, Guangsen ^a   Yi, Yan ^a   Xiao, Le ^a   Pei, Minfei ^a   Liu, Sufang ^a   Luo, Yunya ^a   Zhong, Haiying ^a   Xu, Yunxiao ^a   Zheng, Wenli ^a   Shen, Jiankai ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

5 hmC; Molecular genetics; Mutation; Myelodysplastic syndromes; Myeloid leukemias and dysplasias; Overall survival; Prognostication; TET2

Indexed keywords

5 HYDROXYMETHYLCYTOSINE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; MOLECULAR MARKER;

ADULT; AGED; ARTICLE; CHINESE; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PATHOGENESIS; PRIORITY JOURNAL; TET2 GENE; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; CYTOSINE; DNA METHYLATION; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; PROTO-ONCOGENE PROTEINS; YOUNG ADULT;

EID: 84879574717     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.778408     Document Type: Article

References (26)

1. Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engi J Med 2009;361:1872-1885.
2. Walter MJ, Ding L, Shen D, et al. Recurrent DNMI3A mutations in patients with myelodysplastic syndromes. Leukemia 2001;25:1153-1158.
3. Nikoloski G, Langemeijer SM, Kuiper RP, et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 2010;42:665-667.
4. PardananiA, PatnaikMM, Lasho IL, et al. Recurrent IDH mutations in high-risk myelodysplastic syndrome or acute myeloid leukemia with isolated del(5q). Leukemia 2010;24:1370-1372.
5. Delhommeau F, Dupont 5, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engi J Med 2009;360:2289-2301.
6. Langemeijer SM, Kuiper RP, Berends M, et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009;41:838-842.
7. Tefferi A, Lim KH, Abdel-Wahab 0, et al. Detection of mutant IET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 2009;23:1343-1345.
8. Figueroa ME, Skrabanek L, Li Y, et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 2009;114:3448-3458.
9. lahiliani M, Koh KP, Shen Y, et al. Conversion of 5-methylcytosine to S-hydroxymethylcytosine in mammalian DNA by MLL partner TEll. Science 2009;324:930-935.
10. Brunning RD, Orazi A, Germing U, et al. Myelodysplastic syndroms/neoplasms, overview. In: Swerdlow SH, Campo E, Harris NL, et al. editors. WHO classification of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. pp 88-93.
11. Greenberg P, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120:2454-2465
12. Den Dunnen JI, Antonarakis SE. Nomenclature for the description of human sequence variations. Hum Genet 2002;109:121-124.
13. Herman JG, Graff JR, Myohanen S, et al. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996;93:9821-9826.
14. Mohr F, Dohner K, Buske C, et al. YET genes: New players in DNA demethylation and important determinants for stemness. Exp Hematol 2011;39:272-281.
15. Jankowska AM, Szpurka H, Tiu RV, et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood 2009;113:6403-6410.
16. Figueroa ME, Abdel-Wahab 0, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010; 18:553-567
17. Thol F, Weissinger EM, Krauter L et al. IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica 2010;95:1668-1674.
18. Ko M, Huang Y, Jankowska AM, et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010;468:839-843.
19. Konstandin N, Bultmann 5, Szwagierczak A, et al. Genomic S-hydroxymethylcytosine levels correlate with TET2 mutations and a distinct global gene expression pattern in secondary acute myeloid leukemia. Leukemia 2011;25:1649-1652.
20. Esteller M. Epigenetics in cancer. N Engl J Med 2008;358: 1148-1159.
21. Gal-Yam EN, Saito Y, Egger G, et al. Cancer epigenetics: Modifications, screening and therapy. Annu Rev Med 2008;59:267 280.
22. Robertson KD, Jones PA. DNA methylation: Past, present and future directions. Carcinogenesis 2000;21:461-467.
23. Quesnel B, Guillerm G, Vereecque R, et al. Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 1998;91:2985-2990.
24. Shen L, Kantarjian H, Guo Y, et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 2010;28:605-613.
25. Bestor TH. The DNA methyltransferases of mammals. Hum Mol Genet 2000;9:2395-2402.
26. Aolci E, Ohashi H, Uchida T, et al. Expression levels of DNA methyltransferase genes do not correlate with pl5IN TUB gene methylation in myelodysplastic syndromes. Leukemia 2003;17: 1903-1904.